Pharmacotherapy of cerebral ischemia

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 12, 2009, Pages 1895-1906

  Ducruet, Andrew F ^a   Grobelny, Bartosz T ^a   Zacharia, Brad E ^a   Hickman, Zachary L ^a   Yeh, Mason L ^a   Connolly Jr , E Sander ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Ischemia; Neuroprotection; Pharmacotherapy; Stroke; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALBUMIN; ALTEPLASE; ANCROD; ARGATROBAN; CITICOLINE; DANOPAROID; DESMOTEPLASE; DISUFENTON SODIUM; EPTIFIBATIDE; FIBRINOLYTIC AGENT; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM SULFATE; MANNITOL; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RETEPLASE; SARUPLASE; STREPTOKINASE; TENECTEPLASE; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CLINICAL TRIAL; DEVICE THERAPY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; EXCITOTOXICITY; HUMAN; LOW DRUG DOSE; MORTALITY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; THROMBUS; TREATMENT FAILURE; TREATMENT OUTCOME;

BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; STROKE; THROMBOLYTIC THERAPY;

EID: 68149183422     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903055095     Document Type: Review

References (114)

1. Truelsen T, Ekman M, Boysen G. Cost of stroke in Europe. Eur J Neurol 2005;12:78-84
2. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181 (Pubitemid 43754289)
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1588 •• The results of the first successful tPA trial in acute stroke.
4. Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009;40:S111-4
5. Orso F, Baldasseroni S, Maggioni AP. The role of thrombolysis in acute ischemic stroke. Herz 2008;33:498-506
6. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry 2008;79:1093-1099
7. Gonzalez ER. Intracoronary thrombolysis to abort heart attacks: wave of the future? JAMA 1981;245:11-13
8. Multicentre Acute Stroke Trial - Italy G. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-1514
9. The Multicenter Acute Stroke Trial - Europe Study G. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-150
10. Donnan G, Davis S, Chambers B, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996;276:961-966
11. Hung CC, Chiou SH. Isolation of multiple isoforms of alpha-fibrinogenase from the Western diamondback rattlesnake, Crotalus atrox: N-terminal sequence homology with ancrod, an antithrombotic agent from Malayan viper. Biochem Biophys Res Commun 1994;201:1414-1423
12. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000;283:2395-2403
13. Hennerici MG, Kay R, Bogousslavsky J, et al. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet 2006;368:1871-1878 • Recent clinical trial describing lack of success using ancrod, a novel thrombolytic agent, in acute stroke in 6 h of symptoms. (Pubitemid 44794528)
14. Available from: www.clinicaltrials.gov; ASP-I: NCT00141011; ASP-II: NCT00300196
15. Wahlgren N, Ahmed N, D valos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2008;369:275-282 • Results of a large study confirming the safety and efficacy tPA in acute stroke in 3 h.
16. Audebert HJ, Kukla C, Vatankhah B, et al. Comparison of tissue plasminogen activator administration management between telestroke network hospitals and academic stroke centers: the telemedical pilot project for integrative stroke care in Bavaria/ Germany. Stroke 2006;37:1822-1827 (Pubitemid 44297736)
17. Schwab S, Vatankhah B, Kukla C, et al. Long-term outcome after thrombolysis in telemedical stroke care. Neurology 2007;69:898-903 (Pubitemid 47329590)
18. Gilligan AK, Thrift AG, Sturm JW, et al. Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit? Cerebrovasc Dis 2005;20:239-244
19. Wang Y, Tsirka S, Strickland S, et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998;4:228-231 (Pubitemid 28138083)
20. Samson AL, Medcalf RL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic. Plasticity 2006;50:673-678
21. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59-64 (Pubitemid 32095643)
22. Su EJ, Fredriksson L, Geyer M, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008;14:731-737
23. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141-150 • Results of an unsuccessful clinical trial of a novel thrombolytic agent using MRI defined criteria in acute stroke up to 9 h after onset of symptoms.
24. Qureshi AI, Siddiqui AM, Suri MFK, et al. Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 2002;51:1319-1329
25. Shaltoni HM, Albright KC, Gonzales NR, et al. Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke? Stroke 2007;38:80-84
26. Parsons MW, Miteff F, Bateman GA, et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009;72:915-921
27. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025
28. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-1251 (Pubitemid 28470336)
29. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a Randomized Controlled Trial. JAMA 1999;282:2019-2026
30. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (Alteplase) 0- to 6-Hour Acute Stroke Trial, Part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke 2000;31:811-816 (Pubitemid 30198420)
31. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774
32. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329 •• Results of a recent study that indicates the safety and efficacy of tPA up to 4.5 h after onset of stroke.
33. Major Ongoing Stroke Trials. Stroke 2008;39:e154-62
34. Larrue V, von Kummer R, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator : a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-441 (Pubitemid 32155231)
35. Barber PA, Darby DG, Desmond PM, et al. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. Neurology 1998;51:418-426
36. Warach S, Gaa J, Siewert B, et al. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995;37:231-241
37. Rother J, Schellinger PD, Gass A, et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke < 6 hours. Stroke 2002;33:2438-2445
38. Darby DG, Barber PA, Gerraty RP, et al. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke 1999;30:2043-2052
39. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-517 (Pubitemid 44871793)
40. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299-309 • A study that describes the clinical effect of perfusing the MRI-defined penumbra.
41. Thomalla G, Schwark C, Sobesky J, et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German Multicenter Study with the pooled data of ATLANTIS, ECASS, and NINDS tPA Trials. Stroke 2006;37:852-858 (Pubitemid 43731921)
42. Reddrop C, Moldrich RX, Beart PM, et al. Vampire bat salivary plasminogen activator (Desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005;36:1241-1246 (Pubitemid 40798746)
43. Liberatore GT, Samson A, Bladin C, et al. Vampire bat salivary plasminogen activator (Desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34:537-543 (Pubitemid 36206361)
44. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73 (Pubitemid 40054177)
45. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-1231 (Pubitemid 43731867)
46. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581
47. Chen Z-M. CAST: randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke. Lancet 1997;349:1641-1649
48. Chen Z, Sandercock P, Pan H, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 2000;31:1240-1249 • Pooled results of two very large trials examining the effect of aspirin in acute stroke. (Pubitemid 30351240)
49. Adams HP Jr, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008;39:87-99
50. Abciximab Emergent Stroke Treatment Trial I. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005;36:880-890
51. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Trial Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998;279:1265-1272
52. Sandercock PA, Counsell C, Kamal AK, et al. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2008;8:CD000024
53. Pancioli AM, Broderick J, Brott T, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR Stroke Trial. Stroke 2008;39:3268-3276
54. Sugg RM, Pary JK, Uchino K, et al. Argatroban tPA Stroke Study: study design and results in the first treated cohort. Arch Neurol 2006;63:1057-1062 (Pubitemid 44232309)
55. Vergouwen MDI, Vermeulen M, de Haan RJ, et al. Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review. J Cereb Blood Flow Metab 2006;27:1293-1308
56. Bereczki D, Mihalka L, Szatmari S, et al. Mannitol use in acute stroke: case fatality at 30 days and 1 year. Stroke 2003;34:1730-1735 (Pubitemid 36842636)
57. Bardutzky J, Schwab S. Antiedema therapy in ischemic stroke. Stroke 2007;38:3084-3094
58. Lutsep HL. Mechanical endovascular acute stroke treatment: here to stay. Expert Rev Med Dev 2008;5:273-274
59. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: A Phase II Randomized Trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4-11
60. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II Study: a randomized controlled trial. JAMA 1999;282:2003-2011
61. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-2605
62. The Interventional Management of Stroke Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke 2004;35:904-911
63. The Interventional Management of Stroke II Trial Iinvestigators. The Interventional Management of Stroke (IMS) II Study. Stroke 2007;38:2127-2135 • Results of a trial investigating interventional methods in acute stroke.
64. Labiche L, Grotta JC. Clinical trials for cytoprotection in stroke. NeuroRx 2004;1:46-70
65. Diener H-C, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II trials. Stroke 2008;39:1751-1758
66. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600
67. Koziol JA, Feng AC. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I Study of NXY-059 for acute ischemic stroke. Stroke 2006;37:2644-2647
68. O'Collins VE, Macleod MR, Donnan GA, et al. 1,026 Experimental treatments in acute stroke. Ann Neurol 2006;59:467-477
69. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-2758 • STAIR criteria for preclinical acute stroke trials.
70. Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 2009;40:577-581
71. Ginsberg MD. Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Stroke 2007;38:1967-1972
72. Sacchetti ML. Is it time to definitely abandon neuroprotection in acute ischemic stroke? Stroke 2008;39:1659-1660
73. Minnerup J, Schäbitz W-R. Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics 2009;6:43-52
74. Saver JL, Kidwell C, Eckstein M, et al. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Pilot Trial. Stroke 2004;35:e106-108 •• The pilot study of magnesium administration in the field in the setting of acute stroke describing the method of rapid enrollment of patients.
75. Available from: http://www.clinicaltrials.gov; NCT00604630
76. Liu R, Suzuki A, Guo Z, et al. Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury. J Neurochem 2006;96:1101-1110
77. Wang L, Zhang Z, Wang Y, et al. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004;35:1732-1737 (Pubitemid 38823656)
78. Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971-975 (Pubitemid 37152934)
79. Li Y, Lu Z, Keogh CL, et al. Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 2006;27:1043-1054 (Pubitemid 46659037)
80. Sirén A, Knerlich F, Poser W, et al. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001;101:271-276 (Pubitemid 32219761)
81. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-14912 (Pubitemid 39410773)
82. Sirén A, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. PNAS 2001;98:4044-4049
83. Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002;22:10291-10301 (Pubitemid 35416867)
84. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505 (Pubitemid 36337492)
85. Lin J-Y, Chung S-Y, Lin M-C, Cheng F-C. Effects of magnesium sulfate on energy metabolites and glutamate in the cortex during focal cerebral ischemia and reperfusion in the gerbil monitored by a dual-probe microdialysis technique. Life Sci 2002;71:803-811
86. Nowak L, Bregetovski P, Ascher P, et al. Magnesium gates glutamate-activated channels in mouse central neurons. Nature 1984;307:462-465 (Pubitemid 14132062)
87. Chi O, Pollak P, Weiss H. Effects of magnesium sulfate and nifedipine on cerebral blood flow during middle cerebral artery ligation in the rat. Arch Int Pharmacodyn Ther 1990;196-205 (Pubitemid 20275308)
88. Izumi Y, Roussel S, Pinard E, Seylaz J. Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1991;11:1025-1030
89. Marinov M, Harbaugh K, Hoopes P, et al. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg 1996;85:117-124 (Pubitemid 26195046)
90. Muir K, Lees K. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev 2003;3:CD001244
91. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 2004;363:439-445 (Pubitemid 38210060)
92. Available from: http://www.clinicaltrials.gov; NCT00059332
93. Clark W, Warach S, Pettigrew L, et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 1997;49:671-678
94. Warach S, Pettigrew L, Dashe J, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 2000;48:713-722 (Pubitemid 30823221)
95. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001;57:1595-1602
96. Clark WM, Williams BJ, Selzer KA, et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999;30:2592-2597
97. Agut J, Font E, Sacristan A, Ortiz J. Radioactivity incorporation into different cerebral phospholipids after oral administration of 14C methyl CDP-choline. Arzneimittelforschung 1983;33:1048-1050
98. Adibhatla RM, Hatcher JF, Dempsey RJ. Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke 2001;32:2376-2381 (Pubitemid 32954811)
99. Fresta M, Puglisi G, Di Giacomo C, Russo A. Liposomes as in-vivo carriers for citicoline: effects on rat cerebral post-ischaemic reperfusion. J Pharm Pharmacol 1994;46:974-981
100. Adibhatla RM, Hatcher JF, Larsen EC, et al. CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke. J Biol Chem 2006;281:6718-6725
101. Yen C-LE, Mar M-H, Zeisel SH. Choline deficiency-induced apoptosis in PC12 cells is associated with diminished membrane phosphatidylcholine and sphingomyelin, accumulation of ceramide and diacylglycerol, and activation of a caspase. FASEB J 1999;13:135-142
102. Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 2002;33:2850-2857 • Pooled results of three clinical trials that suggests the neuroprotection in patients receiving citicoline. (Pubitemid 35462855)
103. Available from: http://www.clinicaltrials.gov; NCT00331890
104. Parkkinen J, Ojala P, Niiranen J, Jolkkonen J. Molecular mechanisms underlying neuroprotective effects of albumin after ischemic stroke. Stroke 2007;38:255-256 (Pubitemid 46184287)
105. Rodriguez de Turco EB, Belayev L, Liu Y, et al. Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J Neurochem 2002;83:515-524 (Pubitemid 35231805)
106. Belayev L, Marcheselli VL, Khoutorova L, et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 2005;36:118-123 (Pubitemid 40054186)
107. Belayev L, Pinard E, Nallet H, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 2002;33:1077-1084 (Pubitemid 34293595)
108. Nimmagadda A, Park H-P, Prado R, Ginsberg MD. Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a Two-Photon Laser-Scanning Microscopy Study. Stroke 2008;39:198-204
109. Belayev L, Liu Y, Zhao W, et al. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32:553-560 (Pubitemid 32155250)
110. Liu Y, Belayev L, Zhao W, et al. Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur J Pharmacol 2001;428:193-201 (Pubitemid 33000141)
111. Ginsberg MD, Hill MD, Palesch YY, et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-I: physiological responses and safety results. Stroke 2006;37:2100-2106 (Pubitemid 44309911)
112. Palesch YY, Hill MD, Ryckborst KJ, et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-II: neurologic outcome and efficacy analysis. Stroke 2006;37:2107-2114 • Results from the pilot trial of albumin administration in acute stroke.
113. Tang J, Li YJ, Mu J, et al. Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats. Neurol Res 2009;31:189-194
114. Available from: http://www.clinicaltrials.gov; NCT00235495